Frank Moosig, MD, PhD; Wolfgang Ludwig Gross, MD, PhD; Kristina Herrmann, MD; Jan Phillip Bremer, MD; Bernhard Hellmich, MD, PhD
Potential Conflicts of Interest: This study was financially supported by GSK, and GSK provided the study medication.
Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome. Ann Intern Med. 2011;155:341-343. doi: 10.7326/0003-4819-155-5-201109060-00026
Download citation file:
Published: Ann Intern Med. 2011;155(5):341-343.
This article has been corrected. The original version (PDF) is appended to this article as a supplement.
Background: Hypereosinophilia plays a critical role in the pathogenesis of the Churg–Strauss syndrome. Interleukin-5 (IL-5) is the most potent inducer of maturation and activation of eosinophils. We demonstrated elsewhere (1) that IL-5 production is increased in the Churg–Strauss syndrome and that interferon-α therapy, which downregulates IL-5 production, can induce remission of this condition (2). However, long-term results with interferon-α and other biological and conventional drugs, such as cyclophosphamide, have been disappointing.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only